A Dark Vector Cognition product

Item 6. EXHIBITS

9K characters. Original on sec.gov ·

Item 6. EXHIBITS

The 3 tables in Item 6. EXHIBITS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).

Exhibit No.Description
22.Subsidiary Issuers of Guaranteed Securities (incorporated by reference to Exhibit 22 of Bristol Myers Squibb Company's Annual Report on Form 10-K filed on February 11, 2026)
31a.Section 302 Certification Letter (filed herewith).
31b.Section 302 Certification Letter (filed herewith).
32a.Section 906 Certification Letter (furnished herewith).
32b.Section 906 Certification Letter (furnished herewith).
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
  • Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Keytruda and Winrevair are trademarks of Merck; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:

2025 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2025MCLmantle cell lymphoma
2seventy bio2seventy bio, Inc.MerckMerck & Co., Inc., Rahway, NJ, USA
ANDAAbbreviated New Drug ApplicationMFmyelofibrosis
AOCLAccumulated other comprehensive lossMiratiMirati Therapeutics, Inc.
AstraZenecaAstraZeneca PLCMMmultiple myeloma
AVDdoxorubicin, vinblastine and dacarbazineMZLmarginal zone lymphoma
BioArcticBioArctic ABNDANew Drug Application
BioNTechBioNTech SENSCLCnon-small cell lung cancer
CelgeneCelgene CorporationNYHANew York Heart Association
CELMoDcereblon E3 ligase modulatoroHCMObstructive Hypertrophic Cardiomyopathy
CERCLAU.S. Comprehensive Environmental Response, Compensation and Liability ActOnoOno Pharmaceutical Co., Ltd
cHLclassical Hodgkins LymphomaPD-1programmed cell death protein 1
CRCcolorectal cancerPD-L1programmed death-ligand 1
CVRContingent value rightPDUFAPrescription Drug User Fee Act
Dr. Reddy's LaboratoriesDr. Reddy's Laboratories, Limited and Dr. Reddy's Laboratories, Inc.PhilochemPhilochem AG
DVddaratumumab, bortezomib and dexamethasonePfizerPfizer, Inc.
ECEuropean CommissionPFSprogression-free survival
EPSearnings per sharePsApsoriatic arthritis
ESCCesophageal squamous cell carcinomaQuarterly Report on Form 10-QQuarterly Report on Form 10-Q for the quarter ended September 30, 2026
ES-SCLCextensive stage small cell lung cancerR&Dresearch and development
EUEuropean UnionRDFVreadily determinable fair values
EvotecEvotec SEREMSrisk evaluation and mitigation strategy
Exchange Actthe Securities Exchange Act of 1934RocheF. Hoffman-La Roche & Co.
FASBFinancial Accounting Standards BoardRRMMrelapsed or refractory multiple myeloma
FDAU.S. Food and Drug AdministrationSanofiSanofi S.A.
GAAPgenerally accepted accounting principlesSARSpecial Administrative Region
GEP-NETsgastroenteropancreatic neuroendocrine tumorsSECU.S. Securities and Exchange Commission
GTNgross-to-netSPCSupplementary Protection Certificate
HCMhypertrophic cardiomyopathySSTR+somatostatin receptor-positive
HengruiJiangsu Hengrui Pharmaceuticals Co., Ltd.SystImmuneSystImmune, Inc.
HHSHealth and Human ServicesTNBCtriple negative breast cancer
IPFidiopathic pulmonary fibrosisUKUnited Kingdom
IPRDin-process research and developmentU.S.United States
IRAInflation Reduction Act of 2022VATvalue added tax
IRSInternal Revenue ServiceVEGF-AVascular endothelial growth factor A
ITInformation Technology

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT)
Date:October 29, 2026By:/s/ Christopher Boerner, Ph.D.
Christopher Boerner, Ph.D. Chair of the Board and Chief Executive Officer
Date:October 29, 2026By:/s/ David V. Elkins
David V. Elkins Chief Financial Officer

Previous: Item 5. OTHER INFORMATION